Micronized dHACM Injectable for the Treatment of Plantar Fasciitis



Status:Recruiting
Conditions:Infectious Disease
Therapuetic Areas:Immunology / Infectious Diseases
Healthy:No
Age Range:21 - 79
Updated:6/9/2018
Start Date:January 8, 2018
End Date:October 2019
Contact:Stanley J Harris
Email:sharris@mimedx.com
Phone:770-651-9100

Use our guide to learn which trials are right for you!

A Phase 3, Prospective, Double-Blinded, Randomized Controlled Trial of the Micronized dHACM Injection As Compared To Saline Placebo Injection In The Treatment Of Plantar Fasciitis

Prospective, double-blinded, randomized controlled trial of the micronized dHACM injection as
compared to the saline placebo injection in the treatment of plantar fasciitis

Approximately 164 patients will be enrolled in this study. Each patient will receive 1
injection and be evaluated for efficacy and safety during a 6-month observation period.
Randomization will be 1:1. The study is expected to be completed within 24 months, inclusive
of enrollment and follow-up of all subjects.

Inclusion Criteria:

1. Confirmed diagnosis of plantar fasciitis for ≥ 1 month (30 days) and ≤ 18 months by
the investigator

2. VAS Pain scale of ≥ 45 mm at randomization

3. Plantar fasciitis with conservative treatment for ≥ 1 month (30 days), including any
of the following modalities:

- RICE

- Stretching exercises

- NSAIDs

- Orthotics

4. Diagnostic X-Ray within 6 months of enrollment showing view of calcaneus negative for
calcaneal fracture or structural abnormalities

5. BMI ≤ 40 kg/m2

6. Age ≥ 21 years and < 80 years

7. Ability to sign Informed Consent and Release of Medical Information Forms

8. Ability to receive and respond to text messages or emails on a daily basis.

Exclusion Criteria:

1. Prior surgery or trauma to the affected site

2. Subjects requiring bilateral plantar fasciitis treatment at time of enrollment

3. Prior use of any lower limb injection therapy, including corticosteroids or PRP in
either limb within the last 3 months

4. Has diabetes either Type I or Type II.

5. Systemic disorders associated with enthesopathy (disorder of entheses, i.e. bone
attachments) such as Gout, Reiter's syndrome, rheumatoid arthritis, etc.

6. The presence of diagnosed comorbidities that can be confused with or can exacerbate
the condition- to be assessed by X-ray - including but not limited to:

- Calcaneal stress fracture

- Nerve entrapment syndrome (diagnosed as Baxter Nerve Syndrome)

- Fat pad atrophy

- Acute traumatic rupture of the plantar fascia

- Calcaneal tumor

- Tarsal tunnel syndrome (diagnosed)

- Significant bone deformity of the foot that may interfere with the study

7. Affected site exhibits clinical signs and symptoms of infection

8. Known allergy or known sensitivity to Aminoglycosides

9. Subjects who are non-ambulatory

10. History of more than 14 days treatment with immuno-suppressants (including systemic
corticosteroids) or cytotoxic chemotherapy within 30 days prior to enrollment, or who
are anticipated to require such medications during the course of the study

11. Prior radiation at the site

12. Use of any investigational drug(s) or therapeutic device(s) within 3 months preceding
enrollment

13. Immune disorders including Systemic Lupus Erythematosus (SLE), Fibromyalgia, Acquired
Immunodeficiency Syndrome (AIDS) or Human Immunodeficiency Virus (HIV)

14. History of any condition (including drug or alcohol abuse, medical or psychiatric
condition) that is likely to impair understanding of or compliance with the study
protocol, in the judgment of the investigator

15. Pregnancy at enrollment or within last 6 months, women who are breastfeeding, or women
of childbearing potential who are planning to become pregnant during the time of the
study OR are unwilling/unable to use acceptable methods of contraception (birth
control pills, barriers, or abstinence)

16. Workers' compensation subjects
We found this trial at
15
sites
1514 Jefferson Hwy.
New Orleans, Louisiana 70121
504-842-3000
Phone: 504-842-8751
Ochsner Medical Center Ochsner Medical Center is located near uptown New Orleans and includes acute...
?
mi
from
New Orleans, LA
Click here to add this to my saved trials
8042 Wurzbach Road
San Antonio, Texas 78229
210-949-0807
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
Altoona, Pennsylvania 16602
Phone: 814-944-4532
?
mi
from
Altoona, PA
Click here to add this to my saved trials
Bay Pines, Florida 33744
Phone: 727-398-6661
?
mi
from
Bay Pines, FL
Click here to add this to my saved trials
Carlsbad, California 92009
Phone: 760-350-5080
?
mi
from
Carlsbad, CA
Click here to add this to my saved trials
Fresno, California 93721
Phone: 559-431-1700
?
mi
from
Fresno, CA
Click here to add this to my saved trials
Las Vegas, Nevada 89119
Phone: 702-696-9005
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Los Angeles, California 90010
Phone: 213-365-0793
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
McAllen, Texas 78501
Phone: 956-999-8399
?
mi
from
McAllen, TX
Click here to add this to my saved trials
Pismo Beach, California 93449
Phone: 805-481-9100
?
mi
from
Pismo Beach, CA
Click here to add this to my saved trials
4800 Friendship Avenue
Pittsburgh, Pennsylvania 15206
Phone: 412-688-7910
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
South Miami, Florida 33143
Phone: 305-662-1444
?
mi
from
South Miami, FL
Click here to add this to my saved trials
State College, Pennsylvania 16801
Phone: 814-272-3751
?
mi
from
State College, PA
Click here to add this to my saved trials
Tucson, Arizona 85723
Phone: 520-792-1450
?
mi
from
Tucson, AZ
Click here to add this to my saved trials
Virginia Beach, Virginia 23464
Phone: 747-523-0414
?
mi
from
Virginia Beach, VA
Click here to add this to my saved trials